Scrip
Face-to-Face: Allon targets tau pathology with lead drug davunetide
25 January 2010
Nancy Faigen
Please Login to read the full article.
25 January 2010
Nancy Faigen
As
Allon Therapeutics prepares to advance its lead drug candidate, davunetide intranasal (formerly AL-108), into proof-of-concept trials for progressive supranuclear palsy (PSP), its chief medical officer,
Dr Steven Whitaker told
Scrip of the company's excitement at its potential as a treatment...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Face-to-face: Evotec CEO tells of turnaround
- Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
